Patent · US Active

Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies

US10941201B2 · kind B2 · utility

2Cited by

5References

17Claims

0Family size

Assignee

Celldex Therapeutics, Inc. · US

Inventors

Tibor Keler · Ottsville, US
Joel Goldstein · New Brunswick, US
Laura A. VITALE · Doylestown, US
Lizhen He · Allentown, US
Tom O'NEILL · Hackettstown, US
Andrea Crocker · New Hope, US
Karuna SUNDARAPANDIYAN · Kendall Park, US
Lawrence J. Thomas · Easton, US
Jenifer WIDGER · Alpha, US

Key dates

Filing date	Aug 6, 2020
Grant date	Mar 9, 2021
Priority date	—
Expiry date	Aug 6, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.